Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
Abmaxis Inc.* |
Y's Therapeutics Co. Ltd.* (Japan) |
Collaboration to develop a human monoclonal antibody targeting an antigen overexpressed in many tumor types |
Abmaxis will discover antibodies specific to the antigen and Y's will further develop the product; Abmaxis gets rights in China and Y's in the rest of the world; financial terms were not disclosed (3/2) |
Access Pharmaceuticals |
Undisclosed delivery company |
Collaboration to assess Access's Nanoparticle Aggregate Technology |
Research will focus on delivery of therapeutic proteins; terms were not disclosed (3/23) |
ActivX |
Gilead Sciences Inc. (GILD) |
ActivX will further characterize the activity of certain compounds supplied by Gilead |
Terms of the deal were not disclosed (4/5) |
AEterna |
Ardana Bioscience Ltd.* (UK) |
Ardana acquired global rights to Teverelix and the underlying microcrystalline suspension technology |
AEterna subsidiary Zentaris GmbH gets an up-front fee, guaranteed fixed annual payments until 2006, and potential royalties; the product is an LHRH antagonist (4/2) |
Affibody AB* (Sweden) |
Mabtech AB* (Sweden) |
Deal to develop diagnostic kits for detecting disease-related proteins |
Affibody will supply affinity ligands to Mabtech, which will develop and commercialize the diagnostics; Affibody would get royalties on resulting sales (4/1) |
Affibody AB* (Sweden) |
Finnzymes Oy* (Finland) |
Affibody will develop specific affinity ligands for use in kits for polymerase chain reaction |
Finnzymes will sell the resulting kits; Affibody is entitled to milestones and royalties, in addition to payment for ligands (3/24) |
Affymetrix Inc. (AFFX) |
Spectral Genomics Inc.* |
Spectral gained a worldwide license to certain Affymetrix patents on DNA arrays for use in the diagnostics market |
The license supports Spectral's Constitutional Chip, to be introduced in 2004, as well as specialty arrays for use in cancer diagnostics; terms were not disclosed (3/1) |
AngioGenex Inc.* |
BioCheck Inc.* |
Deal to develop cancer diagnostic and prognostic products based on the Id-gene platform technology |
BioCheck gets rights to develop and sell products based on AngioGenex's technology; AngioGenex would get royalties on resulting products (4/22) |
AnorMED Inc. (Canada; |
NeoRx Corp. (NERX) |
NeoRx acquired rights, outside Japan, to AMD473, a platinum- based cancer agent |
AnorMED got $2M up front and could earn up to $13M in milestones, as well as royalty payments of up to 15% (4/5) |
Archemix Corp.* |
Eyetech Pharmaceuticals Inc. (EYET) |
Collaboration to discover new aptamers for use in treating ophthalmic diseases |
Archemix gets an undisclosed up-front payment, as well as milestones and royalties on resulting products; Eyetech will be responsible for all clinical development (4/14) |
Avant Immuno- |
Adprotech Ltd.* (UK) |
Adrotech got nonexclusive rights to certain components of Avant's intellectual property in complement inhibition |
Avant gets undisclosed up-front fees and potential milestone and royalty payments (4/7) |
Biobase GmbH* (Germany) |
GPC Biotech AG (Germany; FSE:GPC) |
GPC licensed Biobase's Transpath signal transduction database |
Terms of the license deal were not disclosed (3/1) |
BioDelivery Sciences International Inc. (BDSI) |
Accentia Inc.* |
BDSI licensed to Accentia a topical formulation of encochleated amphotericin B |
Accentia will pay BDSI royalties of 12%-14% on U.S. sales of the product for chronic sinusitis; BDSI retains worldwide rights to oral and intravenous formulations (4/13) |
Biomira Inc. (Canada; BIOM) |
Prima BioMed Ltd. (Australia; ASX:PRR) |
Biomira is providing Prima unit CancerVac access to its MUC1 protein for use with CancerVac's Mannan-MUC1 fusion protein therapeutic vaccine |
Biomira acquired 10% of CancerVac and an option for exclusive worldwide rights to the product following Phase IIa trials in ovarian cancer; CancerVac could get up to $15.4M in up- ront and milestone payments, as well as royalties, from that part of the deal (3/10) |
Cerus Corp. (CERS) |
MedImmune Inc. (MEDI) |
Deal to use Cerus' technology with MedImmune's program targeting the EphA2 protein to develop cancer vaccines |
Cerus gets an undisclosed up-front payment and development funding, as well as potential milestones and royalties; MedImmune is responsible for clinical testing and commercialization (4/21) |
Cognia Corp.* |
BioSeek Inc.* |
BioSeek licensed the Cognia Molecular information management system |
Terms of the deal were not disclosed (4/22) |
Crucell NV (the Netherlands; CRXL) |
NeoTropiX Inc.* |
License agreement for Crucell's PER.C6 technology covering R&D in viral therapy in oncology |
NeoTropix gets nonexclusive rights in exchange for undisclosed up- ront and annual payments: NeoTropiX has an option for a commercial license (3/16) |
CyDex Inc.* |
Array BioPharma Inc. (ARRY) |
Array got rights to use CyDex's Captisol system in formulation studies |
Terms of the deal were not disclosed (3/9) |
CyDex Inc.* |
Gilead Sciences Inc. (GILD) |
Gilead gained limited use of CyDex's Captisol formulation system |
Details of the deal were not disclosed (3/4) |
Discovery Partners International |
Vertex Pharmaceuticals Inc. (VRTX) |
DPI will use its rapid library synthesis and medicinal chemistry to help advance a Vertex research program |
Terms of the drug-discovery chemistry agreement were not disclosed (4/19) |
DMI |
Biosite Inc. (BSTE) |
Biosite got certain diagnostic rights to cysteinylated albumin, a biomarker for ischemia |
DMI would get milestones and royalties on resulting diagnostics; Biosite would get royalties on any products DMI commercializes that are covered by DMI's licenses under the agreement (3/4) |
EraGen Biosciences Inc.* |
Promega Corp.* |
License deal giving Promega exclusive rights to quantitative gene- xpression assays for the life science research market |
Promega got global distribution rights to resulting assays, which will incorporate EraGen's nucleic acid detection system (3/9) |
EsbaTech AG* (Switzerland) |
Viventia Biotech Inc.* (Canada) |
Deal to investigate if EsbaTech's antibody technology can enhance characteristics of Viventia antibodies, with a view to developing cancer drugs |
EsbaTech gets an up-front payment and research funding; Viventia has an option to license the technology for clinical development, in exchange for milestones and royalties (3/16) |
Evotec OAI AG (Germany; FSE:EVT) |
Panacos Pharmaceuticals Inc.* |
Deal under which Panacos will use medicinal chemistry from Evotec to identify candidates for HIV |
Terms of the deal were not disclosed (3/25) |
Ganymed Pharmaceuticals AG* (Germany) |
Genmab A/S (Denmark; CSE: GEN) |
Genmab licensed Ganymed's GT43 cancer target |
Ganymed is entitled to undisclosed license fees and milestone and royalty payments (4/26) |
Genencor International Inc. (GCOR) |
Innogenetics NV (Belgium; Euronext:INNX) |
Genencor is selling its therapeutic vaccine program to Innogenetics |
Genencor's collaboration with Epimmune Inc. will be transferred in the deal; Genencor will get $10M in the first year and up to $87M in development milestones, as well as sales royalties (3/30) |
Genomics Collaborative Inc.* |
Celestar-Lexico Sciences Inc.* |
Partnership to combine technologies to create a large-scale profile of genes expressed in human breast cancer |
If a pilot study is successful, the companies would increase the scale of the expression database, and ultimately partner to market the database (3/31) |
Geron Corp. (GERN) |
XenoTrans Ltd.* (Australia) |
XenoTrans got rights to use Geron's nuclear transfer technology to produce transgenic pigs for transplantation uses |
Geron gets a 25% equity interest in XenoTrans, and will receive a share of the company's future revenues (4/27) |
Geron Corp. (GERN) |
Xcellsyz Ltd.* (UK) |
Xcellsyz got a nonexclusive license to Geron's human telomerase reverse transcriptase technology for research uses |
The license is limited to cell lines that also include a recombinant conditionally inducible oncogene; Geron gets a license fee, equity in Xcellsyz and royalties on any sales (3/29) |
InDex Pharmaceuticals AB* (Sweden) |
Serono SA (Switzerland; NYSE:SRA) |
Serono receives exclusive worldwide rights to InDex's Kappaproct for ulcerative colitis and potentially other inflammatory diseases |
InDex will receive an initial fee, R&D funding and potential milestone payments, which together could total $35M if the product gains approval in one indication; InDex also could get sales royalties (2/23)# |
Inpharmatica Ltd.* (UK) |
Biotica Technology Ltd.* (UK) |
Inpharmatica will provide ADME services to Biotica for two years |
Biotica intends to develop rapamycin analogues and other anti-proliferatives; terms were not disclosed (4/19) |
Isis Pharmaceuticals Inc. (ISIS) |
Alnylam Pharmaceuticals Inc.* |
The companies are combining technology and expertise to develop RNAi therapeutics |
Alnylam paid Isis $5M for licenses to RNAi patents, and could pay more based on development and licensing; Isis invested $10M in Alnylam, and will provide access to capabilities in development and manufacturing; the broad deal includes other provisions calling for payments to each other or the sharing of resulting revenues (3/11) |
IviGene Corp.* |
Oragenics Inc. (OTC BB:OGEN) |
Oragenics licensed applications of a technology that enables the identification of targets implicated in the onset and progression of disease |
Oragenics gained exclusive worldwide rights in cancer and tuberculosis, as well as in agricultural and other nonhuman uses; IviGene would get royalties from any resulting products or sublicenses, and potential milestone payments (3/4) |
MakScientific LLC* |
Endo Pharmaceuticals Inc. (ENDP) |
Endo got exclusive worldwide rights to MakScientific's library of compounds with selective cannabinoid receptor agonist activity |
The license covers the areas of pain and certain central nervous system disorders; Endo will make an undisclosed up-front payment and potentially will pay milestones and royalties (3/1) |
Manteia SA* (Switzerland) |
Lynx Therapeutics Inc. (LYNX) and Solexa Ltd.* (UK) |
The companies jointly acquired rights from Manteia to technology for DNA colony generation |
The planar cluster technology eventually will replace Lynx's Megaclone technology and be combined with Solexa's sequencing biochemistry; terms were not disclosed (3/25) |
Medarex Inc. Co. Ltd. (MEDX) |
Sinova Biotech (China; OTC BB:SNVBF) |
Sinova will conduct preclinical tests of a fully human antibody to SARS provided by Medarex |
Medarex and the University of Massachusetts Medical School shipped a sample of the antibody; details were not disclosed (4/26) |
Merix Bioscience Inc.* |
Geron Corp. (GERN) |
Geron acquired exclusive rights to use Merix technology in therapeutic cancer vaccines using telomerase as an antigen |
Geron issued Merix 5M shares that were valued at about $44.8M; Geron also got co-exclusive rights to use the technology in cancer vaccines using other antigens, and Merix retains rights outside of telomerase; they also agreed to a cross-licensing deal covering new technology in the field (3/10) |
Micromet AG* (Germany) |
BioInvent International AB (Sweden; SSE:BINV) |
BioInvent got a nonexclusive license to the Micromet and Enzon Pharmaceuticals Inc. single-chain antibody patents |
BioInvent will use the technology in discovery programs; Micromet gets an up-front payment, annual fees and potential sublicensing fees, all of which will be shared with Enzon (4/21) |
Micromet AG* (Germany) |
Arizeke Pharmaceuticals Inc.* |
Arizeke got a nonexclusive license to use Micromet's single- chain antibody technology for developing drug delivery technologies |
Micromet gets an up-front fee and annual payments, as well as milestone and royalty payments on resulting products (3/29) |
Morphochem AG* (Germany) |
The Genetics Co. Inc.* (Switzerland) |
Morphochem will use its structural biology tools to support the beta-secretase program at The Genetics Co. |
Terms of the deal were not disclosed (3/30) |
Neose Technologies |
MacroGenics Inc.* |
Neose will apply its technologies to MacroGenics proteins to improve their therapeutic properties |
MacroGenics can take a limited number of compounds into development; MacroGenics will fund further development; Neose is entitled to various option, milestone and royalty payments as products are developed (4/26) |
NeuroSearch A/S (Denmark; CSE:NEUS) |
PainCeptor Pharma Corp.* (Canada) |
PainCeptor acquired exclusive rights to undisclosed technology for use in pain programs |
NeuroSearch gained a stake of 14.7% in the company formed by the merger of Antalium Inc. and NeuroCeptor Inc. (3/22) |
NuVue Technologies Inc.* |
ThromboGenics Ltd.* (Ireland) |
Collaboration on development of plasmin-based products to treat visual disorders |
ThromboGenics got access to technology for induction of posterior vitreous detachment to use with its recombinant microplasmin; terms were not disclosed (3/10) |
Ortec International Inc. (OTC BB:ORTN) |
ES Cell International Pte. Ltd.* (Singapore) |
Ortec will supply ESI with human skin cells in a collaboration to develop human embryonic stem cell-derived cell therapy products |
Ortec gets undisclosed up-front payments and potential milestones and royalties (4/28) |
Phylos Inc.* |
Cosmix Molecular Biologicals GmbH (Germany) |
Cosmix acquired nonexclusive rights to the PROfusion mRNA peptide display technology |
Terms of the deal were not disclosed; Cosmix is a subsidiary of Gryphon Therapeutics Inc. (4/5) |
Poly-Med Inc.* |
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
Angiotech licensed from Poly-Med a portfolio of absorbable and biodegradable polymers and drug delivery technologies |
Terms of the deal, which expands a relationship started in 2001, were not disclosed; they will collaborate to develop products from the licensed technologies (4/14) |
ProMetic Life Sciences Inc. (Canada; TSE:PLI) |
Serono SA (Switzerland; NYSE:SRA) |
Laboratories Serono SA gained access to ProMetic's protein purification technology |
Serono will fund development of an affinity adsorbent to isolate and purify a protein of interest; terms were not disclosed (3/10) |
Purely Proteins Ltd.* (UK) |
Inhibox Ltd.* (UK) |
Companies will offer discovery services based on combining their computational and screening technologies |
The program began with drug-screening programs for families of human phosphatases, kinases and proteases; terms were not disclosed (4/22) |
RMR Technologies LLC* |
Viragen Inc. (AMEX:VRA) |
Viragen acquired rights to a gene delivery technology to be used to develop avian transgenic technology |
The agreement with RMR and the University of South Florida covers electroporationtechnology; it will be used to develop a platform for producing human therapeutic protein drugs (3/30) |
Scynexis Inc.* |
Norak Biosciences Inc.* |
Scynexis will identify new leads for Norak's drug targets by producing compound libraries and then optimizing clinical candidates |
Norak gets exclusive worldwide rights to resulting products in exchange for undisclosed technology access fees and other compensation for Scynexis technologies and services (4/13) |
SemaCo Inc.* |
CancerVax Corp. (CNVX) |
CancerVax got an exclusive, worldwide sublicense to telomere homologue oligonucleotide technology for use in cancer applications |
CancerVax also has a right of first refusal for other applications of the T-oligos technology, which was developed at Boston University and licensed to SemaCo, which was formed by a BU researcher (3/15) |
Structural GenomiX Inc.* |
Serono SA (Switzerland; NYSE:SRA) |
SGX will apply its FAST tech- nology to generate lead compounds for Serono kinase and phosphatase targets |
SGX will receive up-front, research and development milestones of up to $68M, as well as royalties on sales; Serono is responsible for development and sales (3/23) |
XOMA Ltd. (XOMA) |
Chiron Corp. (CHIR) |
Exclusive, multiproduct collaboration on the development of antibody products for cancer |
Costs and revenues will be shared on a 70- 30 basis, with Chiron's share being 70%; XOMA will receive $10M and a loan facility of up to $50M to fund its share of development expenses (3/1) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before Feb. 27 but was not included in the previous chart. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
